13162 Federal Register / Vol. 62, No. 53 / Wednesday, March 19, 1997 / Notices

Date: April 9, 1997.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4138,

Telephone Conference.

Contact Person: Dr. Anthony Chung,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4138, Bethesda,

Maryland 20892, (301) 435–1213.

Name of SEP: Clinical Sciences.

Date: April 14, 1997.

Time: 10:45 a.m.

Place: NIH, Rockledge 2, Room 4140,

Telephone Conference.

Contact Person: Dr. Larry Pinkus, Scientific

Review Administrator, 6701 Rockledge Drive,

Room 4140, Bethesda, Maryland 20892, (301)

435–1214.

Name of SEP: Clinical Sciences.

Date: April 15, 1997.

Time: 1:00 [p.m.

Place: NIH, Rockledge 2, Room 4112,

Telephone Conference.

Contact Person: Dr. Gopal Sharma,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4112, Bethesda,

Maryland 20892, (301) 435–1783.

Name of SEP: Clinical Sciences.

Date: April 17, 1997.

Time: 1:00 p.m.

Place: NIH, Rockledge 2, Room 4112,

Telephone Conference.

Contact Person: Dr. Gopal Sharma,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4112, Bethesda,

Maryland 20892, (301) 435–1783.

Name of SEP: Clinical Sciences.

Date: April 21, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 4100,

Telephone Conference.

Contact Person: Dr. Jeanne N. Ketley,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4100, Bethesda,

Maryland 20892, (301) 435–1789.

Name of SEP: Biological and Physiological

Sciences.

Date: April 22, 1997.

Time: 1:30 p.m.

Place: NIH, Rockledge 2, Room 5196,

Telephone Conference.

Contact Person: Ms. Carol Campbell,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5196, Bethesda,

Maryland 20892, (301) 435–1257.

Name of SEP: Clinical Sciences.

Date: April 23, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 4100,

Telephone Conference.

Contact Person: Dr. Jeanne N. Ketley,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4100, Bethesda,

Maryland 20892, (301) 435–1789.

Purpose/Agenda: To Review Small

Business Innovation Research.

Name of SEP: Microbiological and

Immunological Sciences.

Date: April 4, 1997.

Time: 8:00 a.m.

Place: Doubletree Hotel, Rockville, MD.

Contact Person: Dr. Gilbert Meier,

Scientific Review Administrator, 6701

Rockledge Drive, Room 4200, Bethesda,

Maryland 20892, (301) 435–1219.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: March 14, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6941 Filed 3–18–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Method of Treating

Established Colitis Using Antibodies

Against IL–12

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I), announces that the

National Institutes of Health is

contemplating the grant of a coexclusive world-wide license to

Genetics Institute, Inc., a Delaware

corporation headquartered in

Cambridge, Massachusetts, and Protein

Design Lab, Inc., a Delaware corporation

headquartered in Mountain View,

California, to practice the inventions

embodied in U.S. Patent Application

08/547,979 and corresponding foreign

patent applications entitled ‘‘Method of

Treating Established Colitis Using

Antibodies Against IL–12’’ in the field

of treatment of inflammatory bowel

disease. These inventions are owned by

the Government of the United States of

America as represented by the

Department of Health and Human

Services.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

SUPPLEMENTARY INFORMATION: The patent

application discloses a method of

treating the established criteria colitis of

an inflammatory bowel disease by

administering the antibodies against IL–

12. A method for evaluating the

effectiveness of the IL–12 antibodies in

reducing the inflammatory response is

also presented.

ADDRESSES: Requests for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated licenses should be

directed to: Jaconda Wagner, J.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: (301)

496–7735, ext. 284; Facsimile: (301)

402–0220. A signed Confidentiality

Agreement will be required to receive

copies of the patent applications.

Applications for a license in the field of

use filed in response to this notice will

be treated as objections to the grant of

the contemplated licenses. Only written

comments and/or applications for a

license which are received by NIH on or

before May 19, 1997, will be considered.

Comments and objections submitted to

this notice will not be made available

for public inspection and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: March 11, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–6856 Filed 3–18–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of the Draft

Environmental Assessment and Land

Protection Plan for the Proposed

Establishment of Black Bayou Lake

National Wildlife Refuge, Ouachita

Parish, LA

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Notice of availability of the

Draft Environmental Assessment and

Land Protection Plan for the Proposed

Plan for the Proposed Establishment of

Black Bayou Lake National Wildlife

Refuge.

SUMMARY: This notice advises the public

that the U.S. Fish and Wildlife,

Southeast Region, proposes to establish

a new national wildlife refuge on Black

Bayou lake near the city of Monroe in

Ouachita Parish, Louisiana. The

purpose of the proposed refuge is to